Mobia Medical

Mobia Medical (Ticker: MOBI US) provides a medical device system for stroke recovery. Its Vivistim Paired Vagus Nerve Stimulation System is described as an FDA-approved solution for chronic ischemic stroke survivors with moderate to severe upper-extremity impairments. For the year ended December 31, 2025, revenue was approximately $32.00 million and net loss was approximately $47.00 million. The company is at the commercial stage. The offering is 100% primary shares.

The scheduled listing date on Nasdaq was May 8, 2026. The proposed offering comprises 10,000,000 shares at an indicative price range of $14.00–16.00 per share. At the indicative range midpoint, the base offering would represent $150.00 million in gross proceeds, excluding any unexercised over-allotment. The indicated IPO market capitalization is $496.00 million.

Bank of America, J.P. Morgan and Goldman Sachs are bookrunners.